-
Capital, M&A & Industry Strategy1 day agoBehind the scenes of 3 Big Pharma layoffs
Three former employees of large pharmas, including Novo and Sanofi, share how they were let go. While they appreciated some aspects of their experiences, such as...
-
Capital, M&A & Industry Strategy1 day agoOruka raises efficacy expectations for long-acting IL-23 inhibitors
BIOCENTURY | PRODUCT DEVELOPMENTORUKA RAISES EFFICACY EXPECTATIONS FOR LONG-ACTING IL-23 INHIBITORSBioCentury’s Clinical Report, Oct. 20–27
-
Capital, M&A & Industry Strategy1 day agoFerring to acquire next-gen IVF startup Gameto for up to $1.4B
The buyout hands Ferring rights to a technology capable of simplifying the lengthy and burdensome process of in vitro fertilization.
-
Capital, M&A & Industry Strategy2 days agoSTAT+: RFK Jr. goes for broke in Iowa
Kennedy on the campaign trail for MAHA, and new rules loom for U.S. investments in Chinese biotech.
-
Capital, M&A & Industry Strategy2 days agoAlphabet’s GV is one of biotech’s most influential corporate investors
The corporate investor arms of Eli Lilly, Sanofi and Pfizer have participated in billions worth of venture capital rounds, but GV is the industry’s biggest spender.
-
Capital, M&A & Industry Strategy2 days agoNovartis takes $1.9bn hit from Avidity takeover in Q3
Novartis's third-quarter results included a $1.9bn impairment relating to its $12bn takeover of Avidity, though CEO insists it remains a good deal.
-
Capital, M&A & Industry Strategy2 days agoAnthropic sets out its biopharma ambitions in IPO doc
Anthropic says it is working with nine of the top 10 pharma groups in its IPO prospectus, which also reiterates AI's "existential risks to humanity."
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
